4D Molecular Therapeutics officer proposes $84.6K sale

Accepted by SEC EDGAR 06/30/2026 - 04:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Scott Bizily, an officer of 4D Molecular Therapeutics, Inc. (FDMT), reported a proposed sale of 6,566 common shares, with an approximate sale date of June 30, 2026, and an aggregate market value of $84,570.08. The past-three-month sales record lists 9,810 common shares sold on June 23, 2026, for gross proceeds of $117,720.00, under the heading “10b5-1 Sales for Scott Bizily.”

Key Figures

Common shares proposed for sale: 6,566 shares Aggregate market value: $84,570.08 Common shares sold: 9,810 shares +1 more

4 metrics

Common shares proposed for sale 6,566 shares Approximate sale date June 30, 2026

Aggregate market value $84,570.08 Proposed sale

Common shares sold 9,810 shares June 23, 2026; past-three-month sales record

Gross proceeds $117,720.00 Sale on June 23, 2026

Key Terms

Rule 10b5-1, Employee Stock Purchase Plan, Exercise of Stock Options

3 terms

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Employee Stock Purchase Plan financial

"Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Exercise of Stock Options financial

"Exercise of Stock Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FDMT shares does Scott Bizily propose to sell?

Scott Bizily reported a proposed sale of 6,566 common shares, with an approximate sale date of June 30, 2026, and an aggregate market value of $84,570.08.

What recent FDMT sales did Scott Bizily report?

The past-three-month sales record lists 9,810 common shares sold on June 23, 2026, for gross proceeds of $117,720.00, under the heading “10b5-1 Sales for Scott Bizily.”

What Rule 10b5-1 plan date is reported for Scott Bizily?

The reported date of plan adoption or giving of instruction, if relying on Rule 10b5-1, is January 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001920738
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	4D Molecular Therapeutics, Inc.
SEC File Number	001-39782
Address of Issuer	5858 Horton Street, #455 Emeryville CALIFORNIA 94608
Phone	5105052680
Name of Person for Whose Account the Securities are To Be Sold	SCOTT BIZILY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6566	84570.08	52276254	06/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2026	Exercise of Stock Options	Issuer			5752	06/30/2026	Cash
Common	11/14/2024	Employee Stock Purchase Plan	Issuer			814	11/14/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SCOTT BIZILY 5858 Horton Street, #455 Emeryville CA 94608	COMMON	06/23/2026	9810	117720.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired under the employee stock purchase plan on 11/14/2024 and 05/14/2025.
Date of Notice	06/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Scott Bizily
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)